Global Diphtheria Treatment Market Size, Share, Forecast Report, 2020-2027

Diphtheria is an infectious disease caused by the bacterium Corynebacterium diphtheria causing severe sore throat and fever leading to narrowing of the air passages and barking cough. Diphtheria may also affect the skin, eyes, or genitals and may cause myocarditis, bleeding and kidney problems.

The global diphtheria treatment market is growing at a slow rate due to high effectiveness and efficiency of the vaccine, falling profitability of vaccine manufacture, side effects associated with vaccines such as type A immune reaction and allergies, variability in the efficacy of vaccines. Financial restraints such as falling returns on investment and the resultant exit of a number of players from vaccine manufacture will affect the future growth of vaccines.

Considering all these factors the market for diphtheria treatment is expected to reach $ 5 billion by the end of 2023, this market is projected to be growing at a CAGR of ~ 3.2 % during 2017-2023.
Key players of Global Diphtheria treatment Market:

Key players profiled in the report are Taj Pharmaceuticals Limited, Bharat Pharmaceuticals, GSK, Sanofi-Pasteur, Merck & Co., Shanghai Institute of Biological Products, Wuhan Institute of Biological Products, Serum Institute of India, Wyeth, Chiron Pharmaceutical Pvt Ltd. and others.

Segments:

The global diphtheria treatment market is segmented on the basis of product type and end users. Based on product type, the market has been segmented as Tetanus Immune Globulin (TIG), Tetanus Toxoid (TT), Tetanus-diphtheria (Td), Diphtheria Toxoid and Pertussis (DTaP). Based on the treatment, the market has been segmented as antitoxin, antibiotics, macrolides and others. Based on the end users, the market has been segmented as hospitals and clinics, academics and research, and others.